Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article.
Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article.
复制标题
DOI:
10.3171/2012.9.jns12815
复制
发表时间:
2012-12
影响因子:
4.1
通讯作者:
Keane RW
中科院分区:
文献类型:
--
作者:
Adamczak S;Dale G;de Rivero Vaccari JP;Bullock MR;Dietrich WD;Keane RW
Traumatic brain injury (TBI), the third most common central nervous system (CNS) pathology, plagues 5.3 million Americans with permanent TBI-related disabilities. To evaluate injury severity and prognosis, physicians rely on clinical variables. Here we seek objective, biochemical markers reflecting molecular injury mechanisms specific to the CNS as more accurate measurements of injury severity and outcome. One such secondary injury mechanism, the innate immune response, is regulated by the inflammasome, a molecular platform that activates caspase-1 and interleukin-1β. We investigated whether inflammasome components are present in the cerebrospinal fluid (CSF) of 23 TBI patients, and whether levels of inflammasome components correlate with outcome. We performed immunoblot analysis of CSF samples from TBI patients and non-trauma controls and assessed outcome five months post-injury by the Glasgow Outcome Scale (GOS). Data were analyzed by Mann-Whitney U tests and linear regression analysis. Patients with severe or moderate cranial trauma exhibited significantly higher CSF levels of the inflammasome proteins apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and NAcht leucine-rich-repeat protein-1 (NALP-1) compared to non-trauma controls (P < 0.0001; P = 0.0029; P = 0.0202, respectively). Expression of each protein correlated significantly with GOS at five months post-injury (P < 0.05). ASC, caspase-1, and NALP-1 were significantly higher in the CSF of patients with unfavorable outcomes, including death and severe disability (P < 0.0001). NALP-1 inflammasome proteins are potential biomarkers to assess TBI severity, outcome, and the secondary injury mechanisms impeding recovery, serving as adjuncts to clinical predictors.